There are two types of prescription drug cost offsets. The first type of cost offset -from prescription drug use -is primarily about the effect of changes in drug quantity (e.g. due to changes in out-of-pocket drug costs) on other medical costs. Previous studies indicate that the cost offsets from prescription drug use may slightly exceed the cost of the drugs themselves. The second type of cost offset -the cost offset from prescription drug innovation -is primarily about the effect of prescription drug quality on other medical costs. Two previous studies (of a single disease or a single country) found that pharmaceutical innovation reduced hospitalization, and that the reduction in hospital cost from the use of newer drugs was considerably greater than the innovation-induced increase in pharmaceutical expenditure. In this study, we reexamine the impact that pharmaceutical innovation has had on hospitalization, employing a different type of 2-way fixed effects research design. In lieu of analyzing different countries over time for a single disease, or different diseases over time for a single country, we estimate the impact that new drug launches that occurred during the period 1982-2015 had on hospitalization in 2015 for 67 diseases in 15 OECD countries. Our models include both country fixed effects and disease fixed effects, which control for the average propensity of people to be hospitalized in each country and from each disease. The number of hospital discharges and days of care in 2015 is significantly inversely related to the number of drugs launched during 1982-2005, but not significantly related to the number of drugs launched after 2005. (Utilization of drugs during the first few years after they are launched is relatively low, and drugs for chronic conditions may have to be consumed for several years to achieve full effectiveness.) The estimates imply that, if no new drugs had been launched after 1981, total days of care in 2015 would have been 163% higher than it actually was. The estimated reduction in 2015 hospital expenditure that may be attributable to post-1981 drug launches was 5.3 times as large as 2015 expenditure on those drugs.
Introduction
To assess whether the benefits of a medical treatment exceed its costs, it is necessary to account for the "cost offsets" that may result from the treatment, as well as the cost of the treatment itself. For example, the true net cost of a drug may depend on potential reductions in the cost of outpatient visits and inpatient care that may result from treatment by the drug.
Previous studies have analyzed two types of prescription drug cost offsets. The first type is the cost offset from prescription drug use. Changes or differences in prescription drug use may be due to changes or differences in out-of-pocket drug costs. In a 2012 report, the Congressional Budget Office (CBO) said that "after reviewing recent research…CBO estimates that a 1 percent increase in the number of prescriptions filled by beneficiaries would cause Medicare's spending on medical services 1 to fall by roughly one-fifth of 1 percent" (Congressional Budget Office 2012, 1). 2 Given the relative magnitudes of Medicare expenditure on drugs and medical services, this suggests that the cost offsets from prescription drug use may slightly exceed the cost of the drugs themselves. 3 The first type of cost offset -from prescription drug use -is primarily about the effect of prescription drug quantity on other medical costs. The second type of cost offset -the cost offset from prescription drug innovation -is primarily about the effect of prescription drug quality on other medical costs. 4 As noted by Jovanovic and Yatsenko (2012) , in "the Spence-Dixit-Stiglitz tradition…new goods [are] of higher quality than old goods." Even if the average quality of new drugs is not higher than the average quality of older drugs, drug innovation could yield cost offsets by increasing drug variety, enabling better matching of drugs to patients.
Studies have shown that new drugs for Crohn's disease, transthyretin amyloid cardiomyopathy, and some types of cystic fibrosis have reduced hospitalization:
• Data from the Phase 3 IM-UNITI study showed that treatment with ustekinumab lowered the risk of Crohn's disease (CD)-related hospitalization, surgery, and the need for alternative biologic therapy in patients with moderate-to-severe CD when compared with placebo. At 2 years, patients in the ustekinumab q12w group were 52% less likely to be hospitalized or require surgery vs patients in the placebo group (hazard ratio [HR] 0.477; 95% CI, 0.238, 0.957; p = 0.033). Patients in the ustekinumab q8w group were 40% less likely to be hospitalized or require surgery (HR 0.601; 95% CI, 0.411, 0.879; p = 0.006). 5
• A phase three clinical trial has shown that tafamidis significantly reduces deaths and hospitalizations in patients with transthyretin amyloid cardiomyopathy, a progressive form of heart failure. Compared to a placebo, the drug reduced deaths by 30 percent and reduced cardiovascular-related hospitalizations by 32 percent. 6
• Ivacaftor is a small molecule drug originally developed to treat the G551D CFTR gene variant that causes about 3-4% of Cystic fibrosis (CF) cases. Inpatient admissions decreased by 55% from 0.57 inpatient admissions per person-year pre-ivacaftor to 0.26 admissions post-ivacaftor, with similar decreases for children and adults. 7 Other studies have provided more general evidence about cost offsets from prescription drug innovation. Lichtenberg (2009a) analyzed the impact of pharmaceutical innovation on hospitalization for a single (albeit important) disease -cardiovascular disease -in 20 OECD countries during the period 1995 -2003 analyzed the impact of pharmaceutical innovation on hospitalization for 131 medical conditions in a single country -the US -during the period 1996-2010. The measure of pharmaceutical innovation used in both studies was the mean vintage of prescription drugs, i.e. the utilization-weighted mean world launch year (or FDA approval year) of drugs consumed. Both studies found that pharmaceutical innovation reduced hospitalization, and that the reduction in hospital cost from the use of newer drugs was considerably greater than the innovation-induced increase in pharmaceutical expenditure.
In this study, we will reexamine the impact that pharmaceutical innovation has had on hospitalization, employing a different type of 2-way fixed effects research design. In lieu of analyzing different countries over time for a single disease, or different diseases over time for a single country, we will analyze 67 diseases in 15 OECD countries in a single year (2015): we will estimate the impact that the new drug launches that occurred during the period 1982-2015 had on hospitalization in 2015 for those medical conditions in those countries. 8 The models we will estimate will include both country fixed effects and disease fixed effects, which control for the average propensity of people to be hospitalized in each country and from each disease. Lichtenberg (2018) used a similar approach to analyze the impact of new drug launches on life-years lost in 2015 from 19 types of cancer in 36 countries. The measure of pharmaceutical innovation we will use to explain hospitalization for medical condition (disease) d in country c in 2015 is the number of drugs used to treat (indicated for) disease d that had ever been launched in country c by the end of year t-k (k = 0, 1, 2, …, 15). 9 We hypothesize the existence of a lag from drug launches to hospitalization because new drugs diffuse gradually. We will provide evidence about the rate of diffusion of new drugs, and investigate whether the drug-age profiles of the hospitalization effect and of drug utilization are consistent.
The two-way fixed effects methodology is feasible because the relative number of drugs launched to treat different diseases varies across countries. This variation is illustrated by Figure 1 , which shows the number of drugs launched In Italy and Mexico for 8 types of cancer during the period 1997-2010. The mean number of drugs launched for these 8 diseases was identical (4.9) in both countries. But Mexico had more drug launches for prostate, breast, and lung cancer, and Italy had more drug launches for skin, ovarian, and bladder cancer. I hypothesize that the ratio of hospitalization in 2015 for the first 3 cancers to hospitalization in 2015 for the latter 3 cancers should have been smaller in Mexico than it was in Italy. Instead of performing the analysis using just these 16 observations (8 diseases * 2 countries), I will perform the analysis on about 1005 observations (67 diseases * 15 countries). In the next section, we describe the econometric model of hospitalization. Data sources are discussed in Section 3. Empirical results are presented in Section 4. Implications of the results are discussed on Section 5. Section 6 concludes.
Econometric Model of Hospitalization
Our analysis of the impact that new drug launches had on hospitalization will be based on the following twoway fixed effects model: ln(Y dc ) = 0−4 LAUNCHES_2011_2015 dc + 5−9 LAUNCHES_2006_2010 dc + 10−14 LAUNCHES_2001_2005 dc + 15−33 LAUNCHES_1982_2000 dc
where Y dc is one of the following variables: Due to data limitations, the number of drugs launched in four different periods are the only disease-and country-specific explanatory variables included in eq. (1). The disease and country fixed effects in the equation control for some unobserved potential determinants of hospitalization, e.g. the country fixed effects (δ c 's) control for a country's attributes (e.g. the size and age structure of its population, and its average income, edu-cational attainment, and health care expenditure) to the extent that they have similar effects on hospitalization from different diseases. 12 If the data were available, we would like to include other regressors in eq. (1), including (1) disease incidence, and (2) the number of non-pharmaceutical medical innovations (e.g. medical device innovations) for disease d that had been launched in country c. However, there is good reason to believe that failure to control for those variables is unlikely to result in overestimation of the magnitudes of the drug launch coefficients; exclusion of those variables may even result in underestimation of the magnitudes of those parameters. Higher disease incidence is likely to result in more hospitalization and a larger number of drug launches:
Previous studies have shown that both innovation (the number of drugs developed) and diffusion (the number of drugs launched in a country) depend on market size. Acemoglu and Linn found "economically significant and relatively robust effects of market size on innovation." Danzon et al. found that "countries with lower expected prices or smaller expected market size experience longer delays in new drug access, controlling for per capita income and other country and firm characteristics" (emphasis added).
Although incidence data are not available for most diseases, data on the incidence (number of new cases diagnosed) in 2012 in 13 countries of six major types of cancer 13 are available. 14 We used those data to analyze the relationships across countries between relative incidence and (1) relative hospitalization, and (2) This suggests that failure to control for incidence in eq. (1) is extremely unlikely to result in overestimation of the magnitudes of the drug launch parameters.
Failure to control for non-pharmaceutical medical innovation (e.g. innovation in diagnostic imaging, surgical procedures, and medical devices) is also unlikely to bias estimates of the effect of pharmaceutical innovation on hospitalization, for two reasons. First, 88% of privately-funded US funding for biomedical research came from pharmaceutical and biotechnology firms (Dorsey 2010) . 15 Second, previous research based on US data (Lichtenberg 2014b (Lichtenberg , 2014c indicated that non-pharmaceutical medical innovation is not positively correlated across diseases with pharmaceutical innovation.
According to eq. (1), hospitalization depends on the number of drugs that had previously been launched to treat a disease. In principle, hospitalization might depend on the number of drug classes instead of, 16 or in addition to, the number of drugs. However, several previous studies (e.g. Lichtenberg 2017) have shown that premature mortality depends only on the number of drugs previously launched, not on the number of drug classes. One possible interpretation of the non-significance of the number of drug classes is that mortality depends on the number of drug classes, but some drug classes may be more important or valuable than other drug classes. Moreover, drug classes that are more important or valuable are likely to have larger numbers of drugs. 17 In other words, mortality is inversely related to the number of drug classes, weighted by their relative importance, and the number of drugs in a class may be a good indicator of the relative importance of the class. This could explain why mortality is related to the number of drugs rather than the number of drug classes.
Our data on drug launches are left-censored: we only have data on drugs launched after 1981. We therefore define LAUNCHES_1982_2000 dc (for example) as the number of post-1981 new chemical entities (i.e. NCEs first launched anywhere in the world after 1981) used to treat disease d that were launched in country c during 1982-2000. Consequently, this measure is subject to error, because LAUNCHES_1982_2000 dc will not (but should) include pre-1982 NCEs that were first launched in country c during 1982-2000. If this measurement error is random, it is likely to bias estimates of β 15-33 towards zero. 18 In eq.
(1), drugs launched in 4 different periods (0-4 years, 5-9 years, 10-14 years, and 15-33 years before 2015) are permitted to have different effects on hospitalization in 2015. The model is specified in this way because the effect of a drug's launch on hospitalization is hypothesized to depend on both the quantity and the quality (or effectiveness) of the drug. Indeed, it is likely to depend on the interaction between quantity and quality: a quality improvement will have a greater impact on mortality if drug utilization (quantity) is high. Drugs launched in the 4 different periods are likely to vary (in opposite ways) with respect to both quantity (in 2015) and quality. Newer drugs are likely to be of higher quality than older drugs. 19 On the other hand, utilization of new drugs tends to be much lower than utilization of old drugs.
To provide evidence about the process of diffusion of new medicines, I estimated the following model, using annual data for the period 1999-2010 on utilization of 744 drugs (molecules) in 11 countries: 20 ln(N_SU mcn ) = mc + n + mcn (4) where N_SU mcn = the number of standard units 21 of molecule m sold in country c n years after it was launched in country c (n = 0, 1, …, 15) ρ mc = a fixed effect for molecule m in country c π n = a fixed effect for age n Data on the launch year of molecule m in country c were obtained from the IQVIA New Product Focus database. Data on the number of standard units of molecule m sold in country c in year t were obtained from the IQVIA MIDAS database. The expression exp(π n − π 10 ) is a "relative utilization index": it is the mean ratio of the quantity of a drug sold n years after it was launched in country c to the quantity of the same drug sold 10 years after it was launched in country c.
Estimates of the "relative utilization index" are shown in Figure 2 . These estimates indicate that it takes 8-10 years for a drug to attain its peak level of utilization. The number of standard units sold 10 years after launch is 73% larger than the number of standard units sold 2 years after launch. The MIDAS data for many countries distinguish between drugs sold to hospitals and drugs sold to other distribution channels (i.e. retail pharmacies). As shown in Figure 3 , those data indicate that the adoption of new drugs occurs earlier in hospitals than it does in other settings: the fraction of a drug's sales that were to hospitals is 43% higher 0-4 years after it was launched than it was 15 or more years after it was launched. 22 
Data Sources

Hospitalization Data
Data on the number of hospital discharges and average length of stay, by diagnosis and country in 2015, were obtained from the OECD Health Statistics database (OECD 2017b). The disease classification scheme is provided in (OECD 2017c) . Data on the number of hospital discharges, by disease and country, are shown in Appendix Table 4 .
Drug Launch Data
Data on drug launches, by country and year , were obtained from the IQVIA New Product Intelligence database.
Drug Indications Data
Data on drug indications were obtained from Theriaque, a database produced by the French Centre National Hospitalier d'Information sur le Médicament Centre National Hospitalier d'Information sur le Médicament (2017) . Data on the number of drugs launched during 1982-2015, by disease and country, are shown in Appendix Table 5 .
Drug Utilization Data
Annual data on the number of standard units of drugs sold, by molecule, country, and year (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) were obtained from the IQVIA MIDAS database. 
Cancer Incidence Data
Empirical Results
Estimates of the drug launch coefficients from eq. (1) are presented in Table 1 . All models include disease fixed effects and country fixed effects. Each model was estimated in two different ways: with disturbances clustered by country, and with disturbances clustered by disease. The clustering choice does not affect the point estimates of the drug launch coefficients (shown in column 1). Columns 2-4 show the standard errors, Z statistics, and p-values when the disturbances are clustered by disease; columns 5-7 show them when the disturbances are clustered by country. To account for heteroskedasticity, all models were estimated by weighted least squares, weighting by DISCHARGES dc . 23 The first four rows of Table 1 show estimates of the coefficients of the drug launch regressors when the dependent variable is ln(DISCHARGES dc ). These estimates are also plotted in Panel A of is not surprising, since the utilization of drugs during the first few years after they are launched is relatively low (Figure 2) , and drugs for chronic conditions may have to be consumed for several years to achieve full effectiveness. The estimate of β [10] [11] [12] [13] [14] indicates that one additional drug for a disease launched during 2001-2005 was associated with a 10% reduction in the number of hospital discharges due to that disease in 2015. The estimate of β 15-33 is about half as large (and only marginally significant (p-value = 0.067) when disturbances are clustered by country), but the difference between the estimates of β 10-14 and β [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] is not statistically significant (p-value = 0.254). Rows 5-8 of Table 1 show estimates of the coefficients of the drug launch regressors when the dependent variable is ln(ALOS dc ); these estimates are also plotted in Panel B of Figure 4 . In contrast to the estimates of the DISCHARGES model, these estimates indicate that the average length of hospital stays in 2015 is significantly inversely related to the number of drugs launched during 2006-2010 and 2011-2015, but is not significantly related to the number of drugs launched during 1982-2000 and 2001-2005 . The finding that average length of stay is inversely related to relatively recent drug launches, despite the fact that overall utilization of new drugs is quite limited, seems consistent with the fact that new drugs diffuse more rapidly in the hospital sector than they do in the retail pharmacy sector (Figure 3) . The sickest patients, who are more likely to be hospitalized, may obtain access to new drugs earlier than less severely ill patients.
Rows 9-12 of Table 1 show estimates of the coefficients of the drug launch regressors when the dependent variable is ln(DAYS dc ); these estimates are also plotted in Panel C of Figure 4 In addition to estimating models in which drug launches were divided into four periods, we estimated models in which drug launches were divided into just two periods: 1982-2005 and 2006-2015 . These estimates, which are shown in rows 13-18 of Table 1 
Discussion
Now we will use the estimates of eq. (1) reported in Table 1 to obtain rough estimates of the reduction in hospital utilization and expenditure attributable to previous drug launches, and compare them to the increases in pharmaceutical expenditure resulting from those launches. These calculations are shown in Table 2 Calculation of the number of 2015 hospital discharges which may have been prevented by drugs launched during 1982-2015 is shown in rows 1-5. The mean reduction (which we denote by Φ) in ln(DISCHARGES) in 2015 attributable to drugs launched after 1981 is Φ = β 0-4 * mean(LAUNCHES_2011_2015 dc ) + β 5-9 * mean(LAUNCHES_2006_2010 dc ) + β 10-14 * mean(LAUNCHES_2001_2005 dc ) + β 15-33 * mean (LAUNCHES_1982_2000 dc ). The estimated ratio of the number of discharges in 2015 in the absence of new drugs to the actual number of discharges = 1/exp(Φ). The estimates imply that, if no new drugs had been launched after 1981, the number of discharges in 2015 would have been 91% (= (1/exp(−0.645)) -1) higher than it actually was. Similarly, as shown in rows 6-10 and 11-15, the estimates imply that, if no new drugs had been launched after 1981, average length of stay in 2015 would have been 38% (= (1/exp(−0.321)) -1) higher than it actually was, and total days of care would have been 163% (= (1/exp(−0.966)) -1) higher than it actually was.
If hospital expenditure is proportional to total days of care, then our estimates imply that, if no new drugs had been launched after 1981, 2015 hospital expenditure would also have been 163% higher than it actually was. Data on both hospital (inpatient curative care) expenditure and prescribed medicine expenditure in 2015 are available for 9 of the 15 countries in our sample. As shown in Table 3 , total hospital expenditure and prescribed medicine expenditure in those 9 countries was $275 billion and $159 billion, respectively. We estimate that, in the absence of any drug launches during 1982-2015, hospital expenditure would have been $448 billion (= 163% * $275 billion) higher than it actually was. IQVIA data indicate that drugs launched during 1982-2015 accounted for just over half (53%) of the prescribed medicine expenditure in those countries in 2015. Therefore, we estimate that, in the absence of any drug launches during 1982-2015, pharmaceutical expenditure would have been $85 billion (= 53% * $159 billion) lower than it actually was. The estimated reduction in 2015 hospital expenditure attributable to post-1981 drug launches was 5.3 (= $448 billion/$85 billion) times as large as 2015 expenditure on those drugs.
This implies that pharmaceutical innovation reduced overall medical expenditure. The magnitude of the hospital cost offset is about twice as large as those estimated in the two studies cited earlier. One of those studies examined only cardiovascular diseases, which account for about 12% of hospital discharges. The hospital cost offset from new cardiovascular drugs may be smaller than the offset from other drugs. The other study was about a single country (the US), which was excluded from our sample due to the absence of 2015 US hospitalization data in the OECD Health Statistics database. The ratio of drug expenditure to hospital expenditure in the US is about 24% higher than it is in 10 countries included in our sample for which comparable data are available; the higher US ratio may be due in part to higher drug prices in the US than in other countries. Lower prices of drugs in other countries could be a reason for the hospital cost offset in those countries to be larger than it is in the US. 24 We have examined the impact of new drug launches on utilization of hospital care, by analyzing data on hospital utilization, by disease and country. Data on utilization of other medical care (e.g. outpatient care, home health care, and nursing home care), by disease and country, are not available. But two previous studies (Lichtenberg 2009b ) based on US data have provided evidence that the introduction and use of new drugs has also reduced utilization of nursing home care, office-based visits, outpatient care, and home health care.
Summary and Conclusions
There are two types of prescription drug cost offsets. The first type of cost offset -from prescription drug use -is primarily about the effect of changes in drug quantity (e.g. due to changes in out-of-pocket drug costs) on other medical costs. Previous studies indicate that the cost offsets from prescription drug use may slightly exceed the cost of the drugs themselves.
The second type of cost offset -the cost offset from prescription drug innovation -is primarily about the effect of prescription drug quality on other medical costs. Two previous studies (of a single disease or a single country) found that pharmaceutical innovation reduced hospitalization, and that the reduction in hospital cost from the use of newer drugs was considerably greater than the innovation-induced increase in pharmaceutical expenditure.
In this study, I reexamined the impact that pharmaceutical innovation has had on hospitalization, using a different kind of two-way fixed effects research design: I estimated the impact that new drug launches during the period 1982-2015 had on hospitalization for 67 medical conditions in 15 OECD countries in 2015. This design enabled me to control for the average propensity of people to be hospitalized in each country and from each disease. The relative number of new drugs launched for different diseases varied across countries.
The number of hospital discharges and days of care in 2015 is significantly inversely related to the number of drugs launched during 1982-2005, but not significantly related to the number of drugs launched after 2005. This is not surprising, since the utilization of drugs during the first few years after they are launched is relatively low, and drugs for chronic conditions may have to be consumed for several years to achieve full effectiveness. The estimates indicated that one additional drug for a disease launched during 1982-2005 was associated with an 8-10% reduction in the number of hospital days due to that disease in 2015.
The average length of hospital stays in 2015 is significantly inversely related to the number of drugs launched after 2005, but not to earlier drug launches. More rapid diffusion of new drugs in the hospital sector than in the retail pharmacy sector may partly explain this finding.
The estimates implied that, if no new drugs had been launched after 1981, the number of discharges in 2015 would have been 91% higher; average length of stay in 2015 would have been 38% higher; and total days of care would have been 163% higher than it actually was. The estimated reduction in 2015 hospital expenditure that may be attributable to post-1981 drug launches was 5.3 times as large as 2015 expenditure on those drugs. The hospital cost offset rate is about twice as large as those estimated in previous studies of a single disease and a single country. The hospital cost offset rate from cardiovascular drugs may be lower than the offset from other drugs, and the hospital cost offset rate outside the US may be larger than it is in the US, perhaps due to lower prices of drugs in other countries.
Utilization of hospital care has declined. In the US, the age-adjusted fraction of people who had one or more hospital stays in the past year declined by 18%, from 7.8% to 6. 4%, between 1997 and 2016. 25 Our estimates are consistent with the hypothesis that the introduction and use of new drugs has made a significant contribution to the decline in hospitalization.
This study is subject to several limitations. Due to left-censoring of our data on drug launches, our measures of the number of drug launches are subject to error, particularly during the 1980s and early 1990s. Also, our measures of the number of drug launches are based on labeled indications only; off-label drug use is not accounted for. Our drug indications data were obtained from a French database, and some drugs launched in other countries have not been launched in France. Our estimates provide evidence about the impact of the launch of drugs for a disease on hospitalization for that disease, but they do not capture possible spillover effects of the drugs on hospitalization for other diseases. Also, our estimates control for the effects on hospitalization of a country's overall health system and macroeconomic conditions, to the extent that those effects do not vary across diseases, but those effects might vary across diseases.
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